• Corpus ID: 8957132

[Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency].

@article{Dayer1981RetentionOM,
  title={[Retention of metabolites of a beta-blocking drug, oxprenolol, in renal insufficiency].},
  author={Pierre Dayer and P. Glasson and A. Gorgia and Luc P. Balant and Jean Fabre},
  journal={Schweizerische medizinische Wochenschrift},
  year={1981},
  volume={111 49},
  pages={
          1915-8
        }
}
The pharmacokinetics in blood of oxprenolol and its glucuro-conjugated metabolites has been investigated in healthy volunteers and hemodialyzed patients; in addition, the effect of the drug on the heart rate has been measured. Renal insufficiency does not modify the elimination kinetics of oxprenolol, but it does lead to massive retention of the glucuro-conjugated derivatives on multiple dosing. The present study failed to show hydrolysis of the conjugates with liberation of the active parent… 
3 Citations
Differential consequences of renal failure on the pharmacokinetics of Oxprenolol and its main metabolite
TLDR
Administration of Oxprenolol does not require dosage adjustement in patients with severe renal failure, and this dose did not result in any major difference in cardiac effect between patients and healthy subjects.
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup
TLDR
Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present, whereas other BAAs were considered Dialyzable, clinical data were too limited to develop recommendations.